Patents by Inventor Ernest Knight
Ernest Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060130730Abstract: A method of assembling a dock is provided. The method includes positioning a first dock module adjacent a second dock module wherein each dock module includes a top surface, a bottom surface, and a plurality of sidewalls extending therebetween. Each top surface includes at least one channel extending between opposed sidewalls, each bottom surface includes at least one pocket therein, and each sidewall includes at least one coupling slot extending from the top surface. A first coupling slot of the first dock module is substantially aligned with a first coupling slot of the second dock module. The method also includes inserting a first coupler into the first coupling slot of the first dock module and into the first coupling slot of the second dock module such that the dock modules are secured to one another.Type: ApplicationFiled: December 22, 2004Publication date: June 22, 2006Inventors: Ernest Knight, Larry Moody
-
Patent number: 6184217Abstract: Disclosed herein are therapeutic methologies utilizing a ring substituted derivative of the indolocarbazole K-252a, the derivative represented by the formula:Type: GrantFiled: June 24, 1997Date of Patent: February 6, 2001Assignee: Cephalon, Inc.Inventors: Thomas M Engber, Forrest A. Haun, Michael S. Saporito, Lisa D. Aimone, Matthew S. Miller, Ernest Knight, Jr.
-
Patent number: 5801190Abstract: Disclosed in this patent document are synthetic, biologically active molecules referred to as fused pyrrolo?2,3-c!carbazole-6-ones. These molecules are represented by the following general formulae: ##STR1## Methods for making and using the fused pyrrolo?2,3-c!carbazole-6-ones are also disclosed.Type: GrantFiled: March 28, 1997Date of Patent: September 1, 1998Assignee: Cephalon, Inc.Inventors: Robert L. Hudkins, James L. Diebold, Ernest Knight, Jr.
-
Patent number: 5705511Abstract: Disclosed herein are compounds referred to as "fused pyrrolocarbazoles" which possess a variety of functional pharmacological activities including effect on the function and/or survival of trophic factor responsive cells; inhibition of enzymatic activity; inhibition of inflammation-associated responses; inhibition of cell growth associated with hyperproliferative states; and inhibition of developmentally programmed motoneuron death. The disclosed compounds are represented by the following general formula: ##STR1## Methodologies for the synthetic production of fused pyrrolocarbazoles are also disclosed, as well as exemplary uses of the compounds.Type: GrantFiled: September 11, 1995Date of Patent: January 6, 1998Assignee: Cephalon, Inc.Inventors: Robert L. Hudkins, Ernest Knight, Jr.
-
Patent number: 5616724Abstract: Disclosed in this patent document are synthetic, biologically active molecules referred to as fused pyrrolo[2,3-c]carbazole-6-ones. These molecules are represented by the following general formulae: ##STR1## Methods for making and using the fused pyrrolo[2,3-c]carbazole-6-ones are also disclosed.Type: GrantFiled: February 21, 1996Date of Patent: April 1, 1997Assignee: Cephalon, Inc.Inventors: Robert L. Hudkins, James L. Diebold, Ernest Knight, Jr.
-
Patent number: 5594009Abstract: Disclosed herein are compounds referred to as "fused pyrrolocarbazoles" which possess a variety of functional activities. The disclosed compounds are represented by the following general formula: ##STR1## Methodologies for the synthetic production of fused pyrrolocarbazoles are also disclosed, as well as exemplary, uses of the compounds.Type: GrantFiled: May 26, 1995Date of Patent: January 14, 1997Assignee: Cephalon, Inc.Inventors: Robert L. Hudkins, Ernest Knight, Jr.
-
Patent number: 5591855Abstract: Disclosed herein are compounds referred to as "fused pyrrolocarbazoles" which possess a variety of functional activities. The disclosed compounds are represented by the following general formula: ##STR1## Methodologies for the synthetic production of fused pyrrolocarbazoles are also disclosed, as well as exemplary uses of the compounds.Type: GrantFiled: April 24, 1995Date of Patent: January 7, 1997Assignee: Cephalon, Inc.Inventors: Robert L. Hudkins, Ernest Knight, Jr.
-
Patent number: 5475110Abstract: Disclosed herein are compounds referred to as "fused pyrrolocarbazoles" which possess a variety of functional activities. The disclosed compounds are represented by the following general formula: ##STR1## Methodologies for the synthetic production of fused pyrrolocarbazoles are also disclosed, as well as exemplary uses of the compounds.Type: GrantFiled: October 14, 1994Date of Patent: December 12, 1995Assignee: Cephalon, Inc.Inventors: Robert L. Hudkins, Ernest Knight, Jr.
-
Patent number: 5418192Abstract: An in vitro method for the production of interferon is set forth. The method involves the culture of monocytes with a new DA15 peptide produced in Daudi cell lines in response to stimulation with interferon gamma.Type: GrantFiled: December 28, 1992Date of Patent: May 23, 1995Assignee: Medical College of Wisconsin Research FoundationInventors: Ernest C. Borden, Michael Recht, Ernest Knight, Jr.
-
Patent number: 4803163Abstract: A protein fraction isolated from tissue cultures of human diploid fibroblasts or lymphoblastoid cells inhibits the growth of heterologous human cells.Type: GrantFiled: July 9, 1986Date of Patent: February 7, 1989Assignee: E. I. Du Pont de Nemours and CompanyInventors: Diana Fahey, Ernest Knight, Jr.
-
Patent number: 4438030Abstract: Antibodies to the twenty-one acid peptide: (X-Ser-Tyr-Asn-Leu-Leu-Gly-Phe-Leu-Gln-Arg-Ser-Ser-Asn-Phe-Gln-Y-Gln-Lys-L eu-Leu).sub.n, where X is Met or Ser, Y is His or Cys and n is 1 to 12; peptide/protein conjugates and antibodies thereto; process for producing the antibodies; and processes for assaying human fibroblast interferon and for purifying it.Type: GrantFiled: March 30, 1982Date of Patent: March 20, 1984Assignee: E. I. Du Pont de Nemours and CompanyInventors: David J. Ganfield, Michael W. Hunkapiller, Ernest Knight, Jr., Bruce D. Korant
-
Patent number: 4341761Abstract: Antibodies to the twenty-one acid peptide: (X-Ser-Tyr-Asn-Leu-Leu-Gly-Phe-Leu-Gln-Arg-Ser-Ser-Asn-Phe-Gln-Y-Gln-Lys-L eu-Leu).sub.n, where X is Met or Ser, Y is His or Cys and n is 1 to 12; peptide/protein conjugates and antibodies thereto; process for producing the antibodies; and processes for assaying human fibroblast interferon and for purifying it.Type: GrantFiled: July 25, 1980Date of Patent: July 27, 1982Assignee: E. I. Du Pont de Nemours and CompanyInventors: David J. Ganfield, Michael W. Hunkapiller, Ernest Knight, Jr., Bruce D. Korant
-
Patent number: 4311639Abstract: The twenty-one amino acid peptides, (X-Ser-Tyr-Asn-Leu-Leu-Gly-Phe-Leu-Gln-Arg-Ser-Ser-Asn-Phe-Gln-Y-Gln-Lys-L eu-Leu).sub.n, where X is Met or Ser, Y is His or Cys and n is 1 to 12, useful for assaying human fibroblast interferon and for purifying it.Type: GrantFiled: July 25, 1980Date of Patent: January 19, 1982Assignee: E. I. Du Pont de Nemours and CompanyInventors: David J. Ganfield, Michael W. Hunkapiller, Ernest Knight, Jr., Bruce D. Korant
-
Patent number: 4278661Abstract: Human interferons produced in the absence of added serum or sera can be purified to greater than 95% protein purity by adsorption on immobilized Cibacron Blue F3G-A and eluting the interferon adsorbed on the Cibacron Blue F3G-A with ethylene glycol in an aqueous buffer solution. The purified interferon in solution can be converted to interferon of uniform molecular weight by heating the interferon solution in the presence of an organic thiol compound.Type: GrantFiled: October 12, 1979Date of Patent: July 14, 1981Assignee: E. I. Du Pont de Nemours and CompanyInventor: Ernest Knight, Jr.